Publications

19 October

The TRIPS Agreement Laid Bare

3 October

Missing Clinical Trial Data in Europe

26 September

Clinical Trial Regulation in Europe

18 July

Intergovernmental Negotiating Body Second Meeting – Statement

15 July

Religion and SRH: Role of faith leaders in Zambia & Burundi

22 June

Snakebite: Case Studies from Kajiado County, Kenya

17 June

HAI statement on the outcome of TRIPS negotiations at WTO MC12

15 June

HAI Statement to Intergovernmental Negotiating Body

25 May

Statement to WHA75 – Health Emergencies

16 May

Access to Insulin – What you need to know at WHA75

16 May

Diabetes Coverage Targets WHA75

15 May

Clinical Trial Integrity and COVID-19

2 May

Response to European Consultation on Compulsory Licensing

13 April

Annual Report 2021

15 February

Interpreting the EU Artificial Intelligence Act for the Health Sector

2 February

Pooled Procurement of Insulin & Associated Supplies

14 December

Report – Community Engagement Meeting on Snakebite Envenoming

3 December

Procurement of Insulins & Associated Supplies

24 November

Medicine Pricing and Access in Europe

27 October

Regulatory Profile for Glucose Self-monitoring Tools

5 October

Diabetes Self-Monitoring Devices in LMICs

21 September

Eudamed and CTIS: Lessons from EudraCT

15 September

Transparency and Medicines Policy in the EU

5 July

Missing clinical trial data in Europe

21 June

Statement to the 23rd WHO Expert Committee on the Selection and Use of Essential Medicines

29 May

Statement to WHA74 on GSPOA

27 May

Statement to WHA74 on Diabetes and Access to Insulin

3 May

Response to the Revision of the EU General Pharmaceuticals Legislation

3 May

HAI Statement on The Oslo Medicines Initiative at the WHO Virtual Consultation with Non-State Actors, 31 March 2021

1 March

Response to EU’s HERA Initiative Consultation